十、结论
在Graves病眼病的患者中，有4%～13%的患者会出现相关性皮肤病变，而在甲状腺皮肤病变的患者中，有20%的患者会有杵状指，且以杵状指为主要表现。甲状腺皮肤病变与GO的发病机制相似，即TSH受体抗体与成纤维细胞上的TSH受体反应，导致成纤维细胞增殖、透明质酸及黏蛋白产生增多。甲状腺皮肤病变容易发生于下肢皮肤的原因，主要是由于位置的易感性和机械性因素所致。
甲状腺皮肤病变的预防及治疗方法与GO相似，包括尽快恢复甲状腺功能，在胫前黏液性水肿病变的早期给予局部糖皮质激素治疗，无效的难治性病例可给予包括糖皮质激素在内的全身治疗。目前尚缺乏针对甲状腺相关性皮肤病有效的特异性治疗。但是，未来任何证明对于GO有效的经验性系统治疗方法，均可用于难治性甲状腺皮肤病变的治疗。甲状腺性杵状指目前还没有特异性的治疗方法，对有严重骨膜反应伴发疼痛者，可予止痛治疗。
参考文献
[1] Schwartz K M, Fatourechi V, Ahmed D D,et al.Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome[J].J Clin Endocrinol Metab, 2002,87:438-446.
[2] Rice S A, Peden NR, McGlynn S, et al.Atypical presentation of infiltrative thyroid dermopathy[J].Clin Exp Dermatol, 2010, 35:56-58.
[3] Pujol R M, Monmany J, Bague S, Alomar A.Graves’disease presenting as localized myxoedematous infiltration in a smallpox vaccination scar[J].Clin Exp Dermatol, 2000,25:132-134.
[4] Buljan-Cvijanovic M, Neal J M, Zemtsov A.Euthyroid pretibial myxedema[J].Endocr Pract, 1998, 4:375-377.
[5] Chen J J, Ladenson P W.Euthyroid pretibial myxedema[J].Am J Med,1987, 82:318-320.
[6] Jung Yuel H, Nack In K, Choong Rim H.A case of primary hypothyroidism associated with pretibial myxedema[J].Kor J Dermatol, 1993, 31:408-411.
[7] Stewart G, Rowland Payne C M E, Croft D N.Hashimoto's thyroiditis associated with dysthyroid eye disease, pretibial myxoedema and thyroid acropachy[J].J R Soc Med,1984,77: 240-243.
[8] Sarkar D, Singh S K, Bandopadhyaya B, et al.Hashimoto's thyroiditis with ophthalmopathy and dermopathy[J].J Assoc Physicians India, 1997,45:331-332.
[9] Iyer S, Bahn R.Immunopathogenesis of Graves’ophthalmopathy: the role of the TSH receptor[J].Best Pract Res Clin Endocrinol Metab,2012,26:281-289.
[10] Bahn RS.Graves’ ophthalmopathy[J].N Engl J Med,2010,362:726-738.
[11] Fatourechi V.Thyroid dermopathy and acropachy[J].Best Pract Res Clin Endocrinol Metab, 2012, 26:553-565.
[12] Davies T F.Trauma and pressure explain the clinical presentation of the Graves’disease Triad[J].Thyroid,2000,10:620-630.
[13] Fatourechi V.Thyroid dermopathy and acropachy[J].Expert Rev Dermatol,2011,6:75-90.
[14] Fatourechi V, Ahmed D D, Schwartz K M.Thyroid acropachy report of 40 patients treated in a single institution in a 26-year period[J].J Clin Endocrinol Metab, 2002,87:5435-5441.
[15] Bartley GB, Fatourechi V, Kadarmas E F, et al.Chronology of Graves’ophthalmopathy in an incidence cohort[J].Am J Ophthalmol,1996,121:426-434.
[16] Chertman M, Assaf R R.An unusual case of pretibial myxedema following long-term treatment of graves'disease[J].Thyroid, 2013,23:A41.
[17] Lohiya S, Lohiya V, Stahl EJ.Pretibial myxedema without ophthalmopathy: an initial presentation of Graves'disease[J].Am J Med Sci, 2013,346:73-75.
[18] Georgala S, Katoulis A C, Georgala C, et al.Pretibial myxedema as the initial manifestation of Graves'disease[J].J Eur Acad Dermatol Venereol, 2002,16:380-383.
[19] Cho S, Choi J H, Sung K J, et al.Graves’disease presenting as elephantiasic pretibial myxedema and nodules of the hands[J].Int J Dermatol,2001,40:276-277.
[20] Omohundro C, Dijkstra J W, Camisa C, et al.Early onset pretibial myxedema in the absence of ophthalmopathy: a morphologic evolution[J].Cutis, 1996, 58:211-214.
[21] Bartley G B, Fatourechi V, Kadrmas E F,et al.Clinical features of Graves’ ophthalmopathy in an incidence cohort[J].Am J Ophthalmol,1996,121:284-290.
[22] Fatourechi V, Garrity J A, Bartley G B, et al.Orbital decompression in Graves’ ophthalmopathy associated with pretibial myxedema[J].J Endocrinol Invest, 1993,16:433-437.
[23] Artuso V.Roiter J.A HI≈hyperthyroid syndrome[J]．Minerva Endocrino1, 2004, 29：71-75．
[24] Cheung H S, Nimni M E, Kamiel M B, et al.Evidence for a fibroblast stimulating factor(s) in serum of patients with pretibial myxedema[J].Clin Res, 1977, 25:A147.
[25] Chang T C, Wu S L, Hsiao Y L, et al.TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor[J].Clin Immunol Immunopathol,1994, 71:113-120.
[26] Stadlmayr W, Spitzweg C, Bichlmair A M,et al.TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves'ophthalmopathy and pretibial myxedema[J].Thyroid, 1997, 7:3-12.
[27] Daumerie C, Ludgate M, Costagliola S,et al.Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy[J].Eur J Endocrinol, 2002,146:35-38.
[28] Heufelder AE, Dutton CM, Sarkar G, et al.Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves’ophthalmopathy and pretibial dermopathy[J].Thyroid,1993,3:297-300.
[29] Zhao P, Deng Y, Gu P, et al.Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid- associated ophthalmopathy[J].Exp Eye Res, 2013,107:65-73.
[30] Smith T J, Hegedus L, Douglas R S.Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves'orbitopathy[J].Best Pract Res, Clin Endocrinol Metab,2012,26: 291-302.
[31] Varewijck A J, Boelen A, Lamberts S W J,et al.Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves’ ophthalmopathy[J].J Clin Endocrinol Metab, 2013,98:769-776.
[32] Shishiba Y, Tanaka T, Ozawa Y, et al.Chemical characterization of high buoyant density proteoglycan accumulated in the affected skin of pretibial myxedema of Graves’disease[J].Endocrinol Jpn, 1986,33:395-403.
[33] Bahn R S.The fibroblast is the target cell in the connective tissue manifestations of Graves’disease[J].Int Arch Allergy Immunol, 1995, 106:213-218.
[34] Gianoukakis A G, Jennings T A, King C S, et al.Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts[J].Endocrinology, 2007, 148:54-62.
[35] Bahn R S, Smith T J, Gorman C A.The central role of the fibroblast in the pathogenesis of extrathyroidal manifestations of Graves’disease[J].Acta Endocrinol Suppl, 1989,121:75-81.
[36] Wortsman J, Dietrich J, Traycoff R B.Preradial myxedema in thyroid disease[J].Arch Dermatol,1981, 117:635-638.
[37] Ishii M, Nakagawa K, Hamada T.An ultrastructural study of pretibial myxedema utilizing improved ruthenium red stain[J].J Cutan Pathol, 1984,11:125-131.
[38] Matsuoka L Y, Wortsman J, Uitto J, et al.Altered skin elastic fibers in hypothyroid myxedema and pretibial myxedema[J].Arch Intern Med, 1985,145:117-121.
[39] Antonelli A, Palla R, Casarosa L et al.IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves’disease: their in vitro solubilization by intravenous immunoglobulin[J].Clin Exp Rheumatol,1996, 14(Suppl.15): S31-S35.
[40] Liao W L, Chen R H, Lin H J, et al.Toll-like receptor gene polymorphisms are associated with susceptibility to Graves’ophthalmopathy in Taiwan males[J].BMC Med Genet, 2010,11:154.
[41] Liao W L, Chen R H, Lin H J, et al.The association between polymorphisms of B7 molecules(CD80 and CD86) and Graves’ophthalmopathy in a Taiwanese population[J].Ophthalmology, 2011,118(3):553-557.
[42] Stan M N & Bahn R S.Risk factors for development or deterioration of Graves’ophthalmopathy[J].Thyroid,2010,20: 777-783.
[43] Schwartz K M, Fatourechi V, Ahmed D D, et al.Dermopathy of Graves'disease (pretibial myxedema):long-term outcome[J].Journal of Clinical Endocrinology& Metabolism, 2002, 87: 438-446.
[44] Fatourechi V, Bartley G B, Eghbali-Fatourechi G Z, et al.Graves’dermopathy and acropachy are markers of severe Graves’ophthalmopathy[J].Thyroid, 2003, 13:1141-1144.
[45] Fatourechi V.Thyroid dermopathy and acropachy[J].Expert Review of Dermatology, 2011, 6: 75-90.
[46] Hofbauer L C, Muhlberg T, Konig A, et al.Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves’ophthalmopathy undergoing orbital radiotherapy[J].Journal of Clinical Endocrinology & Metabolism, 1997, 82: 2244-2247.
[47] van der Heide F, Dijkstra A, Weersma R K, et al.Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis[J].Inflammatory Bowel Disease, 2009, 15: 1199-1207.
[48] Prabhakar B S, Bahn R S, Smith T J.Current perspective on the pathogenesis of Graves’disease and ophthalmopathy[J].Endocr Rev, 2003, 24:802-835.
[49] Smith T J.Fibroblast biology in thyroid diseases[J].Curr Opin Endocrinol Diabetes, 2002, 9:393-400.
[50] Rapoport B, Alsabeh R, Aftergood D, et al.Elephantiasic pretibial myxedema: insights into and a hypothesis regarding the pathogenesis of extrathyroidal manifestations of Graves’disease[J].Thyroid, 2000,10:685-692.
[51] Davies T F.Trauma and pressure explain the clinical presentation of the Graves'disease triad[J].Thyroid,2000,10: 629-630.
[52] Singh S P, Ellyin F, Singh S K, et al.Case report:Elephantiasis-like appearance of upper and lower extremities in Graves’dermopathy[J].Am J Med Sci,1985, 290:73-76.
[53] Schwartz K M, Ahmed D D, Ahmed I, et al.Development of localized myxedema in a skin graft[J].Int J Dermatol,2002, 41:401-403.
[54] Missner S C, Ramsay E W, Houck H E, et al.Graves’disease presenting as localized myxedema in a thigh donor graft site[J].J Am Acad Dermatol, 1998, 39:846-849.
[55] Lrngrund M，Warnatz K, Uhll M, et a1．EMO syndrome as a late explanation for pretibial swelling[J]．Rheumatology，2001，40：357-358．
[56] Kiljanski J，Nebes V, Wall J R．Significance of tissue specific and tissue non．specific autoimmune reactions of Graves’disease[J]．Clin Exp Rheumatol，1996，15(Suppl): 69-76．
[57] Hasani-Ranjbar S, Mohajeri-Tehrani M R.Localized myxedema of the toe: a rare presentation of graves’dermopathy[J].Arch Iran Med, 2008, 11:326-329.
[58] Katsambas A, Pantazi V, Giannakopoulou H, et al.Localized myxedema in Grave’s disease confined to the toes[J].Int J Dermatol, 2000, 39:953-954.
[59] Chang A, Hsieh A T.Localized myxedema of the foot: a rare presentation of graves’dermopathy[J].J Exp Clin Med, 2013,5:124-125.
[60] Ishizawa T, Sugiki H, Anzai S, et al.Pretibial myxedema with Graves’disease: a case report and review of Japanese literature[J].J Dermatol, 1998, 25:264-268.
[61] Gitter D G, Sato K.Localized hyperhidrosis in pretibial myxedema[J].J Am Acad Dermatol, 1990,23:250-254.
[62] Tatnall FM, Sarkany I.Profuse hyperhidrosis localized to pretibial myxedema[J].Br J Dermatol, 1985,113:65-66.
[63] Siegler M, Retetoff S.Pretibial myxedema: a reversible cause of foot drop due to entrapment of the peroneal nerve[J].N Engl J Med,1976, 294:1383-1384.
[64] Albers S E, Fenske N A.Exuberant tumoral lesions on the dorsum of the foot.Pretibial myxedema[J].Arch Dermatol,1991,127(247-248):250-251.
[65] Shiraishi T, Hanami Y, Oyama N, et al.A case of nodular pretibial myxedema[J].J Dermatol, 2010, 37:106.
[66] Chen Y M, Chen H H, Lan J L,et al.Nodular mucinosis in Graves disease mimicking gouty tophi[J].J Clin Rheumatol,2010,16:287-289.
[67] Hunzeker C M, Kamino H, Walters R F, et al.Nodular pretibial myxedema[J].Dermatol Online J, 2008, 14:8.(https://www.daowen.com)
[68] Gopie P, Naraynsingh V.Severe pretibial myxedema[J].Int J Low Extrem Wounds, 2011,10:91-92.
[69] Wright A L, Buxton P K, Menzies D.Pretibial myxedema localized to scar tissue[J].Int J Dermatol,1990,29:54-55.
[70] Forgie J C, Highet A S, Kelly SA.Myxoedematous infiltrate of the forehead in treated hypothyroidism[J].Clin Exp Dermatol, 1994, 19:168-169.
[71] Kim B J, Kazim M.Prominent premalar and cheek swelling: a sign of thyroid-associated orbitopathy[J].Ophthal Plast Reconstr Surg, 2006, 22:457-460.
[72] Takahashi Y, Nakagawa Y, Fujishima F, et al.A swollen index finger as a presentation of thyroid dermopathy[J].Intern Med, 2010, 49:1831.
[73] Ogrin C.Increased bone alkaline phosphatase and isolated subcortical bone uptake of technetium-99 m hydroxymethylene diphosphonate in the lower extremities in a patient with Graves’disease: a distinctly unusual variant of Graves’acropachy[J].Thyroid,2008,18:1227-1229.
[74] Alvarez-Garrido H, Najera L, Garrido-Rios A A,et al,Borbujo J (2014) Acral persistent papular mucinosis: Is it an under-diagnosed disease? [J].Dermatology Online J,2008,20,21757.
[75] Shlyankevich J, George E, Stetsenko G,et al.Granulomatous variant of scleromyxedema mimicking a drug reaction[J].J Am Acad Dermatol, 2013, 1:AB86.
[76] Wang P, Yang H J, Ran Y P.Localized papular mucinosis with IgA nephropathy a case report[J].Arch Dermatol,2011, 147:599-602.
[77] Kerns M J, Mutasim D F.Focal cutaneous mucinosis in Graves disease: relation to pretibial myxedema[J].Am J Dermatopathol, 2010,32:196-197.
[78] Rongioletti F, Donati P, Amantea A, et al.Obesityassociated lymphoedematous mucinosis[J].J Cutan Pathol, 2009, 36:1089-1094.
[79] Kim K J, Kim H H, Chang S E, et al.A case of pretibial mucinosis without thyroid disease[J].J Dermatol, 2002,29:383-385.
[80] Jackson E M, English I J C.Diffuse cutaneous mucinoses[J].Dermatol Clin, 2002, 20:493-501.
[81] Mir M, Jogi R, Rosen T.Pretibial mucinosis in a patient without Graves disease[J].Cutis, 2011, 88:300-302.
[82] Volke V, Matjus S.Unilateral pitting edema of leg as a manifestation of Graves’disease: a case report[J].J Med Case Rep, 2012, 6:258.
[83] Hiroi N, Sakamoto Y, Urita Y, et al.Graves’disease with intractable diarrhea, chylous ascites, and chylothorax: a case report[J].Thyroid.2007;16:1299-303.
[84] Batal O, Hatem SF.Radiologic case study[J].Thyroid Acropachy Orthopedics, 2008, 31(2): 98-100.
[85] Vanhoenacker F M, Pelckmans M C, De Beuckeleer L H,et al.Thyroid acropachy: correlation of imaging and pathology[J].Eur Radiol, 2001, 11:1058-1062.
[86] King L R.A case study of peculiar soft tissue and bony changes in association with thyroid disease[J].J Clin Endocrinol Metab,1959, 19:1323-1330.
[87] Pineda C, Martinez-Lavin M.Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition[J].Rheum Dis Clin North Am, 2013, 39:383-400.
[88] Tan M N, Bahn R S.Risk factors for development or deterioration of Graves’ophthalmopathy[J].Thyroid,2010,20:777-783.
[89] Cawood T J, Moriarty P, O’Farrelly C,et al.Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link[J].J Clin Endocrinol Metab, 2007,92:59-64.
[90] Hegedus L, Brix T H, Vestergaard P.Relationship between cigarette smoking and Graves’ophthalmopathy[J].J Endocrinol Invest, 2004, 27:265-271.
[91] Lauerberg P, Wallin G, Tallstedt L, et al.TSH-receptor autoimmunity in Graves’disease after therapy with antithyroid drugs, surgery, or radioactive iodine: a 5-year prospective randomized study[J].Eur J Endocrinol, 2008,158:69-75.
[92] Lai A, Sassi L, Compri E, Marino F,et al.Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves’orbitopathy: a retrospective cohort study[J].J Clin Endocrinol Metab,2010, 95:1333-1337.
[93] Moleti M, Mattina F, Salamone I, et al.Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves’ophthalmopathy[J].Thyroid, 2003,13: 653-658.
[94] Matsuoka L Y, Wortsman J, Carlisle K S, et al.The acquired cutaneous mucinoses[J].Arch Intern Med, 1984,144:1974-1980.
[95] 鹿斌，叶红英，张朝云，等.甲状腺功能亢进症相关性 EMA 综合征4例报道并文献复习[J].中华内分泌代谢杂志，2015 ，31（9）： 790-792.
[96] Lindsey R.Baden, M.D,Editor, Thyroid Ophthalmopathy,Dermopathy and Acropachy[J].The New England Journal of Medicine Nengl Jmed, 2016,21 :261.
[97] Bartalena L, Marccocci C, Bogazzi F,et al.Use of corticosteroids to prevent progression of Graves ophthalmopathy after radioiodine therapy of hyperthyroidism[J].N Engl J Med, 1989,321:1349-1352.
[98] Bartalena L.Prevention of Graves’ophthalmopathy[J].Best Pract Res Clin Endocrinol Metab, 2012, 26:371-379.
[99] Bartalena L, Marcocci C, Bogazzi F,et al.Relation between therapy for hyperthyroidism and the course of graves’ophthalmopathy[J].N Engl J Med,1998,338:73-78.
[100] Stan M N, Duraski J M, Brito J P, et al.Cohort study on radioactive iodine -induced hypothyroidism:implications for Graves’ophthalmopathy and optimal timing for thyroid hormone assessment[J].Thyroid, 2013,23:620-625.
[101] Stan M N, Garrity J A, Bahn R S.The evaluation and treatment of graves ophthalmopathy[J].Med Clin North Am, 2012, 96:311-328.
[102] Bahn R S, Burch H B, Cooper D S, et al.Hyperthyroidism and other causes of thyrotoxicosis; management guidelines of the american thyroid Association and american association of clinical endocrinologists[J].Endocr Pract, 2011, 17:456-520.
[103] Marcocci C, Kahaly G J, Krassas G E, et al.European Group on Graves O.Selenium and the course of mild Graves’orbitopathy[J].N Engl J Med, 2011,364:1920-1931.
[104] Chiovato L, Latrota L E, Braverman LE,et al.Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigen[J].Ann Intern med,2003, 139:246-251.
[105] Moleti M, Violo M A, Montanini D,et al.Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe Graves’orbitopathy (GO): a prospective, randomized, single-blind clinical trial[J].J Clin Endocrinol Metab, 2014, 99:1783.
[106] Nwatsock J F, Taieb D, Tessonnier L, et al.Radioiodine thyroid ablation in graves'hyperthyroidism: merits and pitfalls[J].World J Nucl Med, 2012, 11:7-11.
[107] Leo M, Marcocci C, Pinchera A,et al.Outcome of Graves’orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial[J].J Clin Endocrinol Metab, 2012,97:E44-48.
[108] Leslie W S, Hankey C R, Lean M E J.Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review[J].QJM, 2007, 100:395-404.
[109] Zang S, Ponto K A, Kahaly G J.Intravenous glucocorticoids for graves’orbitopathy: efficacy and morbidity[J].J Clin Endocrinol Metabol, 2011,96:320-332.
[110] Wiersinga W M.Graves’orbitopathy: management of difficult cases[J].Ind J Endocrinol Metab,2012,16:S150-152.
[111] Deng A, Song D.Multipoint subcutaneous injection of long-acting glucocorticoid as a cure for pretibial myxedema[J].Thyroid, 2011,21:83-85.
[112] Vannucchi G, Campi I, Covelli D, et al.Treatment of pretibial myxedema with dexamethasone injected subcutaneously by mesotherapy needles[J].Thyroid,2013, 23:626-632.
[113] Susser W S, Heermans A G, Chapman M S,et al.Elephantiasic pretibial myxedema :a novel treatment for an uncommon disorder[J].J Am Acad Dermatol, 2002,46:723-726.
[114] Bernardi J M, Malone J.Thyroid dermopathy localized to areas of injury and responsive to complete decongestive physiotherapy[J].J Am Acad Dermatol, 2011, 64:1219-1220.
[115] Kumar S, Iyer S, Bauer H,et al.A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves’orbital fibroblasts: inhibition by an IGF-1 receptor blocking antibody[J].J Clin Endocrinol Metab,2012, 97:1681-1687.
[116] Perziale N, Kovacs S C, Thomas C B, et al.Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders[J].J Clin Neuromuscul Disease, 2011, 13:63-67.
[117] Levy J M, Hasney C P, Freidlnder P L, et al.Combined mycophenolate mofetil and prednisone therapy in tamoxifen-and prednisone-resistant Reidel’s thyroiditis[J].Thyroid, 2010, 20:105-107.
[118] Turcu A F, Kumar S, Neumann S, et al.A small molecule antagonist inhibits thyrotropin receptor antibodyinduced orbital fibro- blast functions involved in the pathogenesis of Graves ophthalmopathy[J].J Clin Endocrinol Metab,2013, 98:2153-2159.
[119] Bahn RS.Autoimmunity and Graves’disease[J].Clinical Pharmacol Ther, 2012,91:577-579.
[120] Botta R, Lisi S, Marcocci C,et al.Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts[J].Thyroid, 2013, 23:92-96.
[121] Zhang C, Zhang X, Ma L, et al.Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves'ophthalmopathy[J].Endocrine, 2012, 41:248-255.
[122] Issafiras H, Corbin J A, Goldfine I D,et al.Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-beta antibody with differential receptor-modulating properties[J].J Pharmacol Exp Ther, 2014, 348:202-215.
[123] Runkle L, Stacey J.Lupus clinical development: will belimumab’s approval catalyses a new paradigm for SLE drug development[J].Expert Opin Biol Ther, 2014,14:491-501.
[124] McCluggage L K.Safety of TNF inhibitors in adolescents and children[J].Adolesc Health Med Ther,2010, 32:1-8.
[125] Michalova K, Lim L.Biologic agents in the management of inflammatory eye diseases[J].Curr Allergy Asthma Rep, 2008,8:339-347.
[126] Bonafoux D, Lee W C.Strategies for TGF-beta modulation: a review of recent patents[J].Expert Opin Ther Pat, 2009,19:1759-1769.
[127] Tanaka T, Narazaki M.A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy[J].Semin Immunol, 2014, 26:88-96.
[128] Carruth B P, Wladis E J.Inflammatory modulators and biologic agents in the treatment of idiopathic orbital inflammation[J].Curr Opin Ophthalmol, 2012, 23:420-426.
[129] Rajasekaran S, Kruse K, Kovey K, et al.Therapeutic role of Anakinra, an interleukin-1 receptor antagonist,in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/ multiple organ dysfunction/macrophage activating syndrome in critically ill children[J].Pediatr Crit Care Med, 2014,15:401-408.
[130] Paridaens D, van den Bosch W A, van der Loos TL,et al.The effect of etanercept on Graves’ophthalmopathy: a pilot study[J].Eye (Lond), 2005, 19:1286-1289.
[131] Noppen M, Velkeniers B, Steenssens L, et al.Beneficial effects of plasmapheresis followed by immunosuppressive therapy in pretibial myxedema[J].Acta Clin Belg,1988,43:381-383.
[132] Kuzuya N, DeGroot L J.Effect of plasmapheresis and steroid treatment on thyrotropin binding inhibitory immunoglobulins in a patient with exophthalmos and a patient with pretibial myxedema[J].J Endocrinol Invest,1982, 5:373-378.
[133] Dandona P, Marshall N J, Bidey S P, et al.Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis[J].Br Med J, 1979, 1:374-376.
[134] Kriss J P.Treatment of exophthalmos and pretibial myxoedema with plasmapheresis[J].Br Med J,1979,1:1149-1150.
[135] Dhaille F, Dadban A, Meziane L, et al.Elephantiasic pretibial myxoedema with upper-limb involvement,treated with low-dose intravenous immunoglobulins[J].Clin Exp Dermatol,2012,37:307-308.
[136] Keith P, Pittelkow M.Spontaneous resolution of Graves pretibial myxedema: a review of Graves dermopathy,associated autoantibody tests, and new treatment modalities[J].J Am Acad Dermatol, 2014, 1:AB119.
[137] Heyes C, Nolan R, Leahy M, et al.Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis[J].Australas J Dermatol,2012, 53:e1-e4.